Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

PCSK9 Inhibitors MeSH Descriptor Data 2026


MeSH Heading
PCSK9 Inhibitors
Tree Number(s)
D27.505.519.186.071.202.685
D27.505.519.389.745.800.506
D27.505.954.557.500.202.685
Unique ID
D000091362
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000091362
Scope Note
Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level.
Entry Term(s)
PCSK9 Inhibitors Cardiovascular
PCSK9 Inhibitors, Cardiovascular
Registry Numbers
0
Previous Indexing
Anticholesteremic Agents (2018-2021)
Public MeSH Note
2022
History Note
2022
Date Introduced
2022/01/01
Last Updated
2022/01/01
PCSK9 Inhibitors Preferred
PCSK9 Inhibitors, Cardiovascular Narrower
page delivered in 0.151s